GLP1R and acute kidney injury: However, GLP-1 RAs are associated with a modestly increased risk of AKI compared to SGLT2 inhibitors in real-world data, but a lower risk compared to DPP-4 inhibitors, sulfonylureas, and basal insulin [6].